Biomea FusionBMEA +7.32%31 Quick Ratio is 4.98 as of Mar. 2026, which is 19% below its 10-year median of 6.17. GuruFocus rates BMEA with a GF Score™ of 31/100. The stock has 1 warning sign investors should review. Among 1,416 Biotechnology companies, Biomea Fusion ranks better than 59.89% on this metric.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Biomea Fusion's quick ratio for the quarter that ended in Mar. 2026 was 4.98.
Biomea Fusion has a quick ratio of 4.98. It generally indicates good short-term financial strength.
The historical rank and industry rank for Biomea Fusion's Quick Ratio or its related term are showing as below:
BMEA'
s Quick Ratio Range Over the Past 10 Years
Min: 0.93 Med: 6.17 Max: 40.57
Current: 4.98
During the past 7 years, Biomea Fusion's highest Quick Ratio was 40.57. The lowest was 0.93. And the median was 6.17.
BMEA's Quick Ratio is ranked better than 59.89% of 1416
companies
in the Biotechnology industry
Industry Median: 3.6
vs BMEA: 4.98
Biomea Fusion (NAS:BMEA) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Biomea Fusion Quick Ratio Related Terms
Biomea Fusion Quick Ratio Historical Data
* Premium members only.
The historical data trend for Biomea Fusion's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Biomea Fusion's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biomea Fusion Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Biomea Fusion's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Biomea Fusion's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Biomea Fusion's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biomea Fusion (BMEA) has a Quick Ratio of 4.98 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Biomea Fusion and its competitors. This is 19% below median its historical median of 6.17. Over the past decade, Biomea Fusion's Quick Ratio has ranged from 0.93 to 40.57. According to the industry distribution chart, Biomea Fusion ranks #568 out of 1416 companies in the Biotechnology industry, placing it in the top 40.1%.
Is Biomea Fusion's Quick Ratio too high?
Biomea Fusion's current Quick Ratio of 4.98 is 19% below median its 10-year median of 6.17. Over the past 10 years, this metric has ranged from a low of 0.93 to a high of 40.57. The Biotechnology industry median Quick Ratio is 3.60. Biomea Fusion's value of 4.98 is 38.3% above this industry median. Based on the distribution chart, Biomea Fusion ranks #568 out of 1416 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Biomea Fusion has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Biomea Fusion's Quick Ratio compare to VRCA and PMN?
According to the Biotechnology industry distribution chart, Biomea Fusion ranks #568 out of 1416 companies for Quick Ratio. This puts Biomea Fusion in the upper half of its industry. The industry median Quick Ratio is 3.60. Biomea Fusion's value of 4.98 is 38.3% above this benchmark. Historically, Biomea Fusion's own Quick Ratio has ranged from 0.93 to 40.57 over the past decade. While the company's 10-year median is 6.17 vs. the industry median of 3.60, Biomea Fusion has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biomea Fusion's current Quick Ratio of 4.98 is 38.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Biomea Fusion and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biomea Fusion's current Quick Ratio is 4.98, which is 19% below median its own 10-year median of 6.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biomea Fusion stock overvalued right now?
Biomea Fusion (BMEA) has a current Quick Ratio of 4.98. The current Quick Ratio is 4.98, which is 19% below median its 10-year median of 6.17 and 38.3% above the Biotechnology industry median of 3.60. Biomea Fusion's overall GF Score™ is 31/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Biomea Fusion (BMEA), the current Quick Ratio is 4.98 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.
31GF Score
Get the complete analysis for BMEA
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BMEA has been successfully added to your 
